{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:50:28Z","timestamp":1791474628931,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81274148"],"award-info":[{"award-number":["81274148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ethnopharmacology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.jep.2013.10.021","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T18:04:37Z","timestamp":1382378677000},"page":"210-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes"],"prefix":"10.1016","volume":"151","author":[{"given":"Shu-Yan","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jep.2013.10.021_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/09059180.00005110","article-title":"The challenge of targeting EGFR: experience with gefitinib in non-small cell lung cancer","volume":"19","author":"Armour","year":"2010","journal-title":"Eur. Respir. Rev."},{"issue":"21","key":"10.1016\/j.jep.2013.10.021_bib2","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jep.2013.10.021_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(06)70725-2","article-title":"Where next for gefitinib in patients with lung cancer?","volume":"7","author":"Blackhall","year":"2006","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.jep.2013.10.021_bib4","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdq207","article-title":"Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Crin\u00f2","year":"2010","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.jep.2013.10.021_bib5","first-page":"v116","article-title":"Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"D'Addario","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jep.2013.10.021_bib6","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1200\/JCO.2003.06.015","article-title":"Cytochrome P450 CYP3A4\/5 expression as a biomarker of outcome in osteosarcoma","volume":"21","author":"Dhaini","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jep.2013.10.021_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF00543794","article-title":"Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism","volume":"25","author":"Dossing","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jep.2013.10.021_bib8","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1124\/dmd.105.006205","article-title":"Gefitinib (Iressa) inhibits the CYP3A4 mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin from irinotecan","volume":"33","author":"Fujita","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jep.2013.10.021_bib9","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1097\/JTO.0b013e318262de4a","article-title":"A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer","volume":"7","author":"Goldberg","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jep.2013.10.021_bib10","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1124\/dmd.110.035873","article-title":"Similarities and differences in the expression of drug-metabolizing enzymes between human hepatic cell lines and primary human hepatocytes","volume":"39","author":"Guo","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jep.2013.10.021_bib11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/mnfr.200600300","article-title":"Clinical assessment of CYP2D6-mediated herb\u2013drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St John's wort, and Echinacea","volume":"52","author":"Gurley","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.jep.2013.10.021_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2011.06.001","article-title":"Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells","volume":"75","author":"Han","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jep.2013.10.021_bib13","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/dmd.107.017335","article-title":"Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction","volume":"36","author":"Harmsen","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jep.2013.10.021_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00045391-200405000-00009","article-title":"The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes","volume":"11","author":"He","year":"2004","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.jep.2013.10.021_bib15","first-page":"97","article-title":"Clinical research of combined xiaoaiping injection with chemotherapy on advanced non-small cell lung cancer","volume":"12","author":"Huang","year":"2007","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.jep.2013.10.021_bib16","series-title":"Zhongyao Dacidian (Encyclopedia of Chinese Materia Medica)","first-page":"1976","author":"Jiangsu New Medicinal College","year":"1977"},{"key":"10.1016\/j.jep.2013.10.021_bib18","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-07-0088","article-title":"Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes","volume":"13","author":"Li","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jep.2013.10.021_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394Ct method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.jep.2013.10.021_bib20","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0031-9422(00)90856-2","article-title":"Polyoxypregnanes from Marsdenia tenacissima","volume":"34","author":"Luo","year":"1993","journal-title":"Phytochemistry"},{"key":"10.1016\/j.jep.2013.10.021_bib21","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1248\/bpb.30.2091","article-title":"Comparison of basal gene expression and induction of CYP3As in HepG2 and human fetal liver cells","volume":"30","author":"Maruyama","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jep.2013.10.021_bib22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/1535-7163.363.3.3","article-title":"Cytochrome P450 enzymes: novel options for cancer therapeutics","volume":"3","author":"McFadyen","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jep.2013.10.021_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/jco.2004.22.14_suppl.581","article-title":"Intratumoral and plasma concentrations of gefitinib (Iressa) in breast cancer patients: preliminary results from a presurgical investigatory study (BCIRG 103)","volume":"23","author":"McKillop","year":"2004","journal-title":"Proceedings of the Annual Meeting\u2014American Society of Clinical Oncology"},{"key":"10.1016\/j.jep.2013.10.021_bib24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/00498250400009171","article-title":"Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man","volume":"34","author":"McKillop","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jep.2013.10.021_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/00498250400026464","article-title":"Cytochrome P450-dependent metabolism of gefitinib","volume":"35","author":"McKillop","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jep.2013.10.021_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/00498250500523253","article-title":"Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition","volume":"36","author":"McKillop","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jep.2013.10.021_bib27","unstructured":"National University Hospital (NUH), Massachusetts General Hospital (MGH), 2008. Hydroxychloroquine and Gefitinib to Treat Lung Cancer. \u3008http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00809237\u3009."},{"key":"10.1016\/j.jep.2013.10.021_bib28","first-page":"26","article-title":"Drug delivery and drug resistance: EGFR-tyrosine kinase inhibitors in non-small cell lung cancer","volume":"3","author":"Olcay","year":"2010","journal-title":"Open Lung Cancer J."},{"key":"10.1016\/j.jep.2013.10.021_bib29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jep.2010.05.002","article-title":"In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica","volume":"130","author":"Pan","year":"2010","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.jep.2013.10.021_bib30","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.jep.2013.10.021_bib31","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3816\/CLC.2006.n.025","article-title":"Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III\/IV non-small-cell lung cancer","volume":"7","author":"Reck","year":"2006","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.jep.2013.10.021_bib32","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations","volume":"26","author":"Sequist","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jep.2013.10.021_bib33","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003088-200544100-00005","article-title":"Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jep.2013.10.021_bib34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003088-200645060-00006","article-title":"Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics","volume":"45","author":"Swaisland","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jep.2013.10.021_bib35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10147-006-0609-y","article-title":"Resistance to gefitinib","volume":"11","author":"Uramoto","year":"2006","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.jep.2013.10.021_bib36","first-page":"936","article-title":"A random study of xiao-ai-ping injection combined with chemotherapy on the treatment of advanced non-small cell lung cancer","volume":"14","author":"Wang","year":"2009","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.jep.2013.10.021_bib37","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.jchromb.2011.05.056","article-title":"Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography\u2013tandem mass spectrometry","volume":"879","author":"Wang","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jep.2013.10.021_bib38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cbi.2004.09.011","article-title":"Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential","volume":"150","author":"Xu","year":"2004","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jep.2013.10.021_bib39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-3565(24)39081-0","article-title":"Detoxication of Vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance","volume":"294","author":"Yao","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jep.2013.10.021_bib40","doi-asserted-by":"crossref","first-page":"e25507","DOI":"10.1371\/journal.pone.0025507","article-title":"EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells","volume":"11","author":"Yokoyama","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jep.2013.10.021_bib41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.steroids.2009.11.003","article-title":"Five new C21 steroidal glycosides from the stems of Marsdenia tenacissima","volume":"75","author":"Zhang","year":"2010","journal-title":"Steroids"}],"container-title":["Journal of Ethnopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378874113007289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378874113007289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T17:45:39Z","timestamp":1746035139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378874113007289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0378874113007289"],"URL":"https:\/\/doi.org\/10.1016\/j.jep.2013.10.021","relation":{},"ISSN":["0378-8741"],"issn-type":[{"value":"0378-8741","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes","name":"articletitle","label":"Article Title"},{"value":"Journal of Ethnopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jep.2013.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}